Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.
about
SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myelomaIs NF-kappaB a good target for cancer therapy? Hopes and pitfallsCritical role of NF-κB in pancreatic cancerInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationTouch and go: nuclear proteolysis in the regulation of metabolic genes and cancerEvaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myelomaMolecular mechanisms of bortezomib resistant adenocarcinoma cellsBortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myelomaProof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myelomapRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levelsDevelopment of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or SorafenibFoxM1 is a general target for proteasome inhibitors.Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcomeClinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell linesApplying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma.Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaBPI3K/p110{delta} is a novel therapeutic target in multiple myeloma.Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.Proteasome inhibition and its therapeutic potential in multiple myelomaGene expression profile alone is inadequate in predicting complete response in multiple myeloma.Distinct regulatory mechanisms of eukaryotic transcriptional activation by SAGA and TFIID.Composite patient reports: a laboratory informatics perspective and pilot project for personalized medicine and translational researchNew insights, recent advances, and current challenges in the biological treatment of multiple myeloma.A novel measure of chromosome instability can account for prognostic difference in multiple myeloma.Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients.Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms MacroglobulinemiaMethyljasmonate displays in vitro and in vivo activity against multiple myeloma cells.Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat.Metabolic signature identifies novel targets for drug resistance in multiple myeloma.A hybrid approach of gene sets and single genes for the prediction of survival risks with gene expression data.The 26S proteasome complex: an attractive target for cancer therapyResponse of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma.KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma.Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma.Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.
P2860
Q24306820-4EC8DB94-5547-4E1B-845F-B77AFA9BE9CEQ24570128-7E948AE7-F148-4714-85C4-E2C8B0CA6121Q26864198-2966087F-8F62-4515-985E-CBF632F8E979Q27002668-7DF3BA3F-D3B9-4971-ADAD-E56D2E49E349Q28068146-763F676B-3409-4398-A231-BFD24123C9D2Q28296718-122AC586-F01A-4127-AAFE-3D66DA4A41FBQ28478538-CA995D77-73D6-4EC9-B32B-DD93BD012EB3Q28534703-B9C505FF-6EAF-48E5-A7BC-BD9728358FACQ28537857-9A0B2B32-F004-4ABF-96C2-C75C0F02E860Q28543035-99AD6903-DF8E-4060-9A8E-8C573E5F1603Q28548663-74C36059-854A-43D1-8062-B84478B6DCADQ33492774-84149995-DAF5-4860-8273-3EDEA9473EBEQ33737846-0BDF6F89-B909-4211-95F6-7E1B67BDAF0CQ33742964-B913C51F-39CF-451B-9CDD-E9D213C8F753Q33846310-9268F444-D1D6-4FA1-84CE-99C416E8151DQ33948719-C801FBBC-E6F7-488F-AA69-1008D63EEB68Q34022979-D377555E-323C-4A08-831B-06F126D7AE6EQ34111440-F62459CF-B506-420C-AA36-29FCCA7F9F4DQ34124937-6075629F-DE53-42AF-AF62-B4B77DC298C4Q34195083-538F4472-74B7-4D4B-B698-E867A93AC8AEQ34343036-32886682-C82F-4DCF-89CC-58744203B30AQ34345502-453E9B3A-191E-4DA0-9D71-5C56CAF788CDQ34478777-92BB513C-161B-40FD-8DCE-B40B3F9CD2D9Q34585178-4512FF72-F837-4EED-AD65-0E523C9ADB11Q34773850-7F61B9F1-50D3-490A-8E2F-ED396E792565Q34805291-7B4BCA7E-B2C8-4D89-BC47-40988B916C9BQ34880376-D9124B24-4275-48F4-9EFF-0F3E2634FD44Q35097338-0F0582D5-788E-4919-BF2F-D9BE606E7562Q35552719-360B1C19-B22E-4B83-830A-2E2B4F60037AQ35607341-DF943A29-A5B0-419C-B420-07C5FF3E1450Q35612105-1F9F518F-BDC4-4F0F-930B-39A612D2373CQ35620335-CA6AEB37-C595-43DB-A821-5FFB431F257AQ35624079-238D7ECB-3B99-4DFE-BF8A-9A108DA27F26Q35643032-2A82C881-EDF8-4086-8B64-69FE946E0B56Q35675837-60804AE2-07D7-47DF-A0D2-147424BA10F6Q35776414-5E7ACD68-B40D-4C7E-8753-ACF8AA1182BFQ36053910-EAED27F6-8545-4993-A0F8-2473D71F0907Q36146344-68035F2E-A203-420A-B683-2C7CCAB1A333Q36155317-FA0ED9C5-F92F-482F-B808-CCFD2A4F412CQ36193181-FC19208A-46D8-4A4B-831B-515139FBDAB9
P2860
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Gene expression profiling and ...... oteasome inhibitor bortezomib.
@en
Gene expression profiling and ...... oteasome inhibitor bortezomib.
@nl
type
label
Gene expression profiling and ...... oteasome inhibitor bortezomib.
@en
Gene expression profiling and ...... oteasome inhibitor bortezomib.
@nl
prefLabel
Gene expression profiling and ...... oteasome inhibitor bortezomib.
@en
Gene expression profiling and ...... oteasome inhibitor bortezomib.
@nl
P2093
P50
P1433
P1476
Gene expression profiling and ...... oteasome inhibitor bortezomib.
@en
P2093
Andrew Fergus
Annemiek Broyl
Anthony Boral
Barb Bryant
Constantine Mitsiades
David Schenkein
Dixie-Lee Esseltine
Erik Koenig
Fenghuang Zhan
George Mulligan
P304
P356
10.1182/BLOOD-2006-09-044974
P407
P577
2006-12-21T00:00:00Z